ACE-031 is an engineered soluble activin type IIB receptor fusion protein studied for its effects on muscle. Human trials show why an increase in lean mass is not enough to establish a useful treatment: functional benefit and safety must also be demonstrated.
CJC-1295 was developed as a long-acting analogue of growth-hormone-releasing hormone. Early human studies demonstrated changes in growth hormone and IGF-1, not proven anti-aging, fat-loss or muscle-performance outcomes. Exact identity is essential because the CJC name is used inconsistently across product listings.
A CJC/ipamorelin blend combines substances investigated through different growth-hormone signaling pathways. A plausible combination mechanism is not a clinical trial of the blend. The first questions are which CJC-related molecule is present, what the individual amounts are, and whether the claimed outcome was actually measured for that combination.
CJC-1295 with DAC refers to the albumin-binding, long-acting research construct associated with the original CJC-1295 studies. Its prolonged hormone effects are experimentally documented. They should not be confused with demonstrated clinical benefits or transferred to a product lacking that modification.
Follistatin is a protein involved in signaling by members of the TGF-beta family. “Follistatin 344” appears in experimental gene-transfer literature, but that does not mean an injectable product sold with the same number reproduces the intervention. The distinction between a gene construct, its processed protein and a short inhibitory fragment is central to evaluating muscle-growth claims.
Growth differentiation factor 11, or GDF-11, is a signaling protein investigated in development, blood biology and aging. Measuring its concentration in people is not the same as administering it. The selected human studies do not establish that raising GDF-11 improves health or reverses aging.
Ghrelin is a hormone involved in appetite and growth-hormone signaling. Direct human experiments show that giving ghrelin can increase short-term food intake. That does not make it a proven long-term strategy for weight management, muscle gain or recovery from illness.
GHRP-2 is a synthetic growth-hormone secretagogue that acts in the ghrelin signaling system. Controlled human experiments demonstrate hormone and appetite responses. These responses are evidence of biological activity, but they are not the same as showing improved strength, recovery or body composition.
GHRP-6 is a synthetic peptide studied for its ability to stimulate growth-hormone secretion. A directly relevant human experiment compared hormone responses to GHRP-6, growth-hormone-releasing hormone and their combination. It did not test an anti-aging program, injury recovery or long-term muscle gain.
Hexarelin is a synthetic peptide studied for growth-hormone-releasing activity. A small human pharmacology study showed responses through several delivery routes. It did not establish that repeated use improves strength, heals injuries or prevents cardiovascular disease.
Human growth hormone is a protein hormone; somatropin is a recombinant medicinal form. Product-specific clinical uses should be distinguished from claims that raising hormone levels rejuvenates otherwise healthy adults. Body-composition changes alone do not establish longer life, greater independence or improved athletic function.
Human menopausal gonadotropin, or hMG, refers to menotropin preparations with follicle-stimulating and luteinizing hormone activity. This is a fertility-medicine topic. It must not be confused with HMB, a different compound discussed in dietary-supplement research.
Ibutamoren, also called MK-677, is an orally studied small-molecule growth-hormone secretagogue, not a peptide. Human trials show that it can raise growth hormone and IGF-1. They also show why a hormone increase should not be presented as proof of improved cognition, physical function or fat loss.
IGF-1 LR3 is a modified analogue of insulin-like growth factor 1, used in experimental research. Its structural changes alter interactions with binding proteins. That biochemical distinction does not establish that it safely builds muscle, repairs injuries or improves recovery in people.
Ipamorelin is a synthetic peptide studied for growth-hormone release and gastrointestinal effects. Human research exists, but the outcome matters: a hormone response is not proof of muscle gain, and a postoperative trial did not demonstrate a significant improvement in its main efficacy comparisons.
Modified GRF 1-29 refers to altered growth-hormone-releasing-factor peptides. Evidence about unmodified GRF or other analogues cannot establish the effects of an unspecified vendor sequence.
Sermorelin is GHRH 1-29 amide, investigated for pituitary growth-hormone release. Pediatric growth studies do not establish anti-aging, fat-loss or performance benefits in healthy adults.
Wolverine Stack is a marketing name for a peptide combination, commonly described as BPC-157 with a TB-500-related ingredient. Its composition must be established before any evidence can be evaluated.